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T cells of the adaptive immune system in mam-
mals play a central role in the fight against patho-
gen invasion. The initiation and resolution of the 
T cell responses must be tightly regulated to 
allow for effective immune protection while 
avoiding inflammation-induced pathology. T cell 
activation is triggered by antigen engagement of 
the TCR, the sole molecule which determines 
the specificity of a T cell (Hannum et al., 1984). 
TCR engagement induces a signaling cascade 
leading to the activation of three major tran-
scription factors: NFAT, AP-1, and NF-B 
(Isakov and Altman, 2002). Among them, NF-B 
plays a particularly important role and is involved 
in regulating almost all important aspects of 
T cell activation, including proliferation, survival, 
and effector functions (Schulze-Luehrmann and 
Ghosh, 2006). Dysregulated NF-B activation 
in T cells has been associated with the develop-
ment of T cell–mediated inflammatory diseases 
and malignancies (Karin and Greten, 2005; Jost 
and Ruland, 2007), highlighting the importance 
of a tightly regulated negative feedback control 
of TCR-induced NF-B activation. Consider-
ing the pivotal role of NF-B in regulating 
T cell activation, it is no surprise that studies 
from the past two decades have identified multi-
ple layers of modulation that contribute to this 
negative feedback control system falling into 
three major categories: (1) TCR recycling in-
duced by phosphorylation of the CD3 chain 
by PKC; (2) degradation of key signaling mol-
ecules, including the CARD11–Bcl-10–MALT1 
(CBM) signalosome component CARD11, 
through phosphorylation by casein kinase 1 
(CK-1), and Bcl-10 through phosphorylation 
by IKK or through ubiquitination by NEDD4, 
Itch, and cIAP2; and (3) negative feedback loop, 
including the well-characterized NF-B–induced 
expression of inhibitory genes such as IB, 
which binds to nuclear NF-B complexes and 
inhibits their function by shuttling NF-B back 
into cytoplasm, and A20, which is a deubiqui-
tinase, and through removing the K63-linked 
polyubiquitin from the signalosome component 
MALT1, leading to the degradation of MALT1 
and the termination of signal transmission to 
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T cell responses in mammals must be tightly regulated to both provide effective immune 
protection and avoid inflammation-induced pathology. NF-B activation is a key signaling 
event induced by T cell receptor (TCR) stimulation. Dysregulation of NF-B is associated 
with T cell–mediated inflammatory diseases and malignancies, highlighting the importance 
of negative feedback control of TCR-induced NF-B activity. In this study we show that in 
mice, T cells lacking miR-146a are hyperactive in both acute antigenic responses and 
chronic inflammatory autoimmune responses. TCR-driven NF-B activation up-regulates 
the expression of miR-146a, which in turn down-regulates NF-B activity, at least partly 
through repressing the NF-B signaling transducers TRAF6 and IRAK1. Thus, our results 
identify miR-146a as an important new member of the negative feedback loop that con-
trols TCR signaling to NF-B. Our findings also add microRNA to the list of regulators that 
control the resolution of T cell responses.
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Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). 
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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In contrast, overexpression of miR-146a produced the opposite 
effects. This change of T cell activation kinetics is correlated with 
altered NF-B activity and changed expression patterns of a set 
of NF-B responsive genes that are responsible for these activi-
ties. Study of miR-146a expression in CD4 and CD8 T cells re-
vealed that NF-B activation induced by TCR stimulation 
up-regulates the expression of miR-146a, which in turn down-
regulates NF-B activity, at least in part through repressing the 
NF-B signaling transducer TRAF6 and IRAK1. Thus, our re-
sults identify miR-146a as a new and quite critical constituent 
of the negative feedback regulatory network modulating TCR 
signaling to NF-B and add miRNA as a novel molecular player 
in the control of the resolution of T cell responses.
RESULTS
miR-146a–deficient T cells are hyperresponsive  
to acute antigen stimulation in vivo
To study the physiological role of miR-146a in the regula-
tion of T cell responses to antigen stimulation, we generated 
OVA-specific OT1 TCR transgenic (Tg) mice that were 
lacking miR-146a. Resting OT1 T cells of WT or miR-146/ 
background were purified and adoptively transferred into 
CD45.1 congenic recipient mice, followed by antigenic 
stimulation with OVA peptide–pulsed DCs and periodic 
bleeding to monitor the transferred T cells for their response 
to antigen priming and boosting (Fig. 1 A). At the time of 
adoptive transfer, both WT and miR-146a/ OT1 T cells 
displayed a similar naive T cell phenotype (CD25CD69C
D62LhiCD44lo; not depicted). This experimental design al-
lowed us to investigate the role of miR-146a as a T cell–
autonomous regulator, modulating their response to antigen 
stimulation in vivo. We found that after antigen priming, 
compared with WT OT1 T cells, miR-146a/ OT1 T cells 
were hyperresponsive, indicated by a higher magnitude of 
peak response (approximately day 7), delayed contraction after 
the peak response (approximately day 7 to day 21), and the 
persistence of a larger pool of antigen-experienced T cells after 
priming response (after day 21; Fig. 1, B and C). Compared 
with WT OT1 T cells, in addition to their higher peak re-
sponse that implied higher proliferation, miR-146a/ OT1 
T cells also displayed a more activated phenotype at the peak re-
sponse (shown as lower CD62L expression on day 7; Fig. 1 D) 
and exhibited increased survival during the contraction phase 
(shown as less Annexin V+ cells on day 14; Fig. 1 E). The 
antigen-experienced miR-146a/ OT1 T cells that persisted 
after priming response were of typical memory cell pheno-
type (CD25CD69CD62Lhi/loCD44hi), similar to their WT 
counterpart (Fig. 1 F) although in higher numbers, suggest-
ing a possible influence on the recall response. Indeed, upon 
antigen boosting at day 46, we observed a hyperresponse of 
the miR-146a/ memory OT1 T cells compared with the 
WT memory OT1 T cells, which was similar in kinetics with 
that of the primary response (shown as higher magnitude of 
the peak response, delayed contraction, and higher number 
of antigen-experienced T cells persisting after the response) 
but was distinctly more exaggerated (Fig. 1, B and C). It is 
NF-B (Schulze-Luehrmann and Ghosh, 2006; Ruland, 2011). 
This list is still under active expansion (Ghosh and Hayden, 
2008; Ruland, 2011).
MicroRNAs (miRNAs), a family of small noncoding 
RNAs which regulate gene expression by base-pairing to the 
3 untranslated region of their target genes, have recently 
emerged as a novel class of posttranscriptional regulators of 
various biological processes ranging from development to 
function, especially in the immune system (Ambros, 2004; 
Bartel, 2004; Baltimore et al., 2008; Tsitsiou and Lindsay, 
2009). Their capacity to coordinately regulate multiple target 
genes makes miRNAs particularly suitable for regulating 
complex signaling cascades like NF-B. Several years ago in 
an effort to screen for miRNAs involved in innate immune 
cell response to microbial infection, we identified three miR-
NAs (miR-132, miR-155, and miR-146a) that are sharply in-
duced upon LPS stimulation (Taganov et al., 2006). Among 
them, miR-146a attracted our attention for its NF-B–
dependent induction and its targeted degradation of NF-B 
signaling transducers TRAF6 and IRAK1, the signature of an 
NF-B negative feedback regulator (Taganov et al., 2006). 
To study the physiological role of miR-146a, we generated 
miR-146a–deficient (miR-146a/) mice and reported that 
they developed chronic hyperinflammatory and autoimmune 
disorder characterized by splenomegaly, lymphadenopathy, 
and multiorgan leukocyte infiltration (Boldin et al., 2011). 
The gradual accumulation of hyperproliferating myeloid 
cells, activated CD4 and CD8 T cells, and autoantibodies in 
miR-146a/ mice indicates that miR-146a is a critical phys-
iological brake to prevent the overactivation of the innate as 
well as the adaptive immune systems (Boldin et al., 2011). 
We showed that constitutive NF-B activation is a major 
contributor to the development of myeloid hyperprolifera-
tion and malignancies in these mice, confirming miR-146a as 
a physiologically negative feedback regulator of NF-B activa-
tion in the innate immune system in vivo (Boldin et al., 2011; 
Zhao et al., 2011). Study of the autoimmune symptoms in the 
miR-146a/ mice led to the finding of a regulatory T cell (Treg 
cell) deficiency resulting in poorly controlled Th1 response, 
likely caused by the dysregulation of the IFN- signaling path-
way (Lu et al., 2010). However, the molecular mechanisms un-
derlying the physiological role of miR-146a as a negative 
regulator of the adaptive immune system, especially its role as 
an autonomous regulator to modulate T cell and B cell re-
sponses to antigen stimulation, remain largely unexplored.
This study focuses on the physiological role of miR-146a 
in regulating T cell response to antigen stimulation in mice 
and its possible involvement in TCR signaling to NF-B 
during T cell activation. We found that in vivo, T cells lack-
ing miR-146a are hyperresponsive to antigen stimulation and 
are prone to induce T cell–mediated hyperinflammatory 
disease. Using a loss-of-function approach, we found that in 
the absence of miR-146a, both CD4 and CD8 T cells exhibited 
hyperresponsiveness after TCR stimulation, indicated by higher 
proliferation, lengthened survival, exaggerated activation 
phenotype, and enhanced effector cytokine production. 
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T cell–autonomous factor regulating T cell–
associated autoimmunity in vivo, in which 
the responding T cells are exposed to the 
constant presence of autoantigen.
miR-146a–deficient T cells are hyperactive 
in chronic inflammatory response in vivo 
and promote the development  
of T cell–associated autoimmunity
We have previously reported the development 
of T cell–related chronic hyperinflammatory 
autoimmune symptoms in miR-146a/ 
mice starting from 6–8 mo, characterized by splenomeg-
aly, lymphadenopathy, and multiorgan inflammation (Lu 
et al., 2010; Boldin et al., 2011; Zhao et al., 2011). There 
is a gradual accumulation of both CD4+ and CD8+ T cells 
of activated phenotype (CD62Llo and CD69hi) in the periph-
eral blood (PB) of miR-146a/ mice that starts as early as 
2 mo, long before their autoimmune symptoms became 
apparent (Fig. 2, A and B). The accumulation of activated 
T cells showed a sharp increase between 4 and 6 mo (Fig. 2, 
A and B), coincident with the appearance of autoimmune 
symptoms and the premature death of miR-146a/ mice 
(Boldin et al., 2011). Examination of miR-146a/ mice surviv-
ing to 1 yr revealed that by that time, the majority of their 
peripheral CD4 and CD8 T cells in their circulation 
likely caused by the combined effect of more memory T cells 
initiating the response and the hyperresponsiveness of these 
cells, suggesting a dual role for miR-146a in the regulation of 
the T cell response upon secondary antigen stimulation.
In summary, these results define a physiological role for 
miR-146a as an autonomous negative regulator of acute 
antigen-specific T cell response in vivo, for both primary 
and recall responses. The results also suggest that miR-146a 
may play an especially profound role modulating the T cell 
response after repetitive antigen stimulation, through regu-
lating both the pool size of the memory T cells resulting 
from the previous effector T cell response and the respon-
siveness of these memory T cells. This possibility prompted 
us to investigate the physiological role of miR-146a as a 
Figure 1. miR-146a–deficient T cells are  
hyperresponsive to acute antigen stimulation  
in vivo. (A) Schematic representation of the experi-
mental design to study the influence of miR-146a 
deficiency on OVA-specific OT1 T cells in response to 
antigen stimulation in vivo. (B–F) Flow cytometry 
analysis of the WT and miR-146a/ OT1 T cells (gated 
as CD8+V5+CD45.2+) in the PB of recipient CD45.1 
congenic mice receiving 5 × 106 WT or miR-146a/ 
OT1 Tg T cells (day 1) followed by prime (day 0) and 
boost (day 46) immunizations. (B) Percentage of WT and 
miR-146a/ OT1 T cells of total CD8+ T cells at the 
indicated time points. (C) Representative contour plots 
showing the quantitation of WT and miR-146a/ OT1 
T cells (pregated on CD8+) at the indicated time points. 
(D) Surface expression of activation marker CD62L on 
WT and miR-146a/ OT1 T cells on day 7 (7 d after 
prime immunization). Representative histogram plots 
and measurements of mean fluorescence intensity 
(MFI) are shown. (E) Apoptosis of WT and miR-146a/ 
OT1 T cells on day 14 (14 d after prime immunization) 
measured by Annexin V staining. Representative histo-
gram plots and measurements of the percentage of 
Annexin V+ OT1 T cells are shown. (F) Phenotype of the 
WT and miR-146a/ OT1 T cells on day 45 (45 d after 
prime immunization). Representative histogram plots 
are shown. Data are presented as mean ± SEM (n = 8) 
and are representative of three independent experi-
ments. *, P < 0.05; **, P < 0.01 (miR-146a/ OT1  
T cells in comparison with the corresponding control 
WT OT1 T cells; for time course experiment, statistics 
of the peak response are shown).
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glomeruli and tubules in kidney, and the gastric mucosa in 
stomach (Fig. 3 E). Infiltrates primarily consisted of CD3+ 
T cells, confirming a T cell–associated autoimmune syn-
drome (Fig. 3 F). Thus, our results suggest that in addition 
to regulating acute T cell response to antigen stimulation, 
miR-146a is also an autonomous negative regulator of T cells 
in chronic inflammatory response in vivo and contributes to 
controlling the development of T cell–associated autoim-
munity. These findings prompted us to study the expres-
sion of miR-146a in T cells, its regulation of the various 
aspects of T cell activation, and the molecular mechanisms 
underlying its regulatory function.
miR-146a induction in mouse CD4 and CD8  
T cells depends on NF-B
We and others have reported the expression of miR-146a in 
mouse peripheral CD4+ T cells, particularly in CD4+CD25+ 
Treg cells (Monticelli et al., 2005; Lu et al., 2010; Boldin et al., 
2011). Further analysis of other T cell compartments revealed 
that miR-146a is also highly expressed in mouse CD8+  
T cells, as well as non-Treg CD4+ T cells (CD4+CD25), albeit 
at a lower level in CD4+CD25 T cells than in CD4+CD25+ 
Treg cells and at a slightly lower level in CD8+ T cells than in 
CD4+CD25 T cells (Fig. 4 A). Of note, both peripheral 
CD4+ and CD8+ T cells express significantly higher levels 
of miR-146a compared with that expressed in thymocytes, 
suggesting a significant role for miR-146a in mature T cell 
function (Fig. 4 A). Expression of miR-146a is further up-
regulated in both CD4+ and CD8+ T cells upon TCR stimu-
lation using anti-CD3/CD28, suggesting that miR-146a 
is directly involved 
in T cell activation 
(80% CD62Llo and 40% CD69hi; Fig. 2, A–C) and in 
the spleen (SP; 80% CD62Llo and 50% CD69hi; Fig. 2, 
D–F) were of the activated phenotype, associated with severe 
multiorgan inflammation and tissue destruction (Boldin et al., 
2011). However, the interpretation of the role of miR-
146a in this T cell hyperinflammatory phenotype is com-
plicated by the multiple abnormalities in miR-146a/ 
mice that may contribute to this phenomenon, including 
the impaired Treg cell function (Lu et al., 2010) and the 
systemic inflammation induced by myeloid hyperprolifer-
ation and malignancies (Zhao et al., 2011). We therefore 
designed an experiment in which we transferred into RAG1/ 
recipient mice Treg cell–depleted WT and miR-146a/ pe-
ripheral T cells, which were then allowed to manifest a 
chronic hyperinflammatory autoimmune response in re-
cipient mice in the absence of Treg cell control (Fig. 3 A; 
Itoh et al., 1999). This adoptive transfer system allowed us 
to confine the miR-146a deficiency to the responding T cells 
and thus to directly assess the role of miR-146a as an autono-
mous factor in regulating chronic T cell inflammatory response 
in vivo. Compared with WT T cells, both miR-146a/ 
CD4+ and CD8+ T cells were hyperresponsive, indicated 
by a higher number of T cells accumulating in SP (Fig. 3 B), 
more extensive proliferation (Fig. 3 C), lower apoptosis 
(Fig. 3 D), and a more activated phenotype (lower CD62L 
and higher CD69; not depicted). Analysis of tissues in-
cluding lung, liver, kidney, and stomach of recipient mice 
receiving miR-146a/ T cell transfer compared with those 
receiving WT T cell transfer also showed a more significant 
mononuclear cell infiltration into these tissues accompany-
ing more severe tissue destruction, evidenced as the destruc-
tion of bronchiole and alveoli in lung, hepatocytes in liver, 
Figure 2. Spontaneous accumulation of 
activated T cells in miR-146a/ mice as 
they age. (A–C) Flow cytometry analysis to 
quantify the CD4 (gated as CD4+) and CD8 
(gated as CD8+) T cells of activated phenotype 
(gated as CD62Llo or CD69hi) in PB of WT or 
miR-146a/ mice. Measurements of the 
percentage of activated CD4 and CD8 T cells 
at the indicated age (A and B) and representa-
tive histogram plots at 1 yr old (C) are shown. 
(D) Flow cytometry analysis to quantify the 
total CD4 (gated as CD4+) and CD8 (gated as 
CD8+) T cells in the SP of 1-yr-old WT or  
miR-146a/ mice. (E and F) Flow cytometry 
analysis to quantify the CD4 (E; gated as 
CD4+) and CD8 (F; gated as CD8+) T cells of 
activated phenotype (gated as CD62Llo or 
CD69hi) in the SP of 1-yr-old WT or miR-146a/ 
mice. Measurements of the percentage of 
activated CD4 and CD8 T cells and representa-
tive histogram plots are shown. Data are pre-
sented as mean ± SEM (n = 8) and are 
representative of three independent experi-
ments. **, P < 0.01 (miR-146a/ T cells in 
comparison with the corresponding control 
WT T cells; for time course experiment, statis-
tics of the end time point are shown).
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abolished in T cells lacking p50 (Fig. 4 B), indicating that 
TCR-induced miR-146a expression is also dependent on 
NF-B. Quantitatively, c-Rel seems to play a more signifi-
cant role than p50 for regulating the basal expression of miR-
146a, whereas p50 seems to be more important than c-Rel 
for regulating the TCR-induced expression of miR-146a. 
These results suggest that different constituents of NF-B 
may be responsible for regulating the expression of miR-
146a and its related functions in T cells at various develop-
mental and activation stages. In this study, we focused on 
(Fig. 4 B). To study the requirement of NF-B for miR-146a 
expression in mouse primary T cells, we analyzed mice defec-
tive for the NF-B subunit p50 (p50/) or c-Rel (c-Rel/). 
In the absence of either p50 or c-Rel, miR-146a expression 
was significantly down-regulated in both thymocytes and 
peripheral CD4+ and CD8+ T cells (Fig. 4 C), indicating that 
NF-B is required for the basal expression of miR-146a in 
both progenitor and mature T cells. Moreover, after TCR 
stimulation, up-regulation of miR-146a was greatly reduced 
in CD4+ and CD8+ T cells lacking c-Rel and was almost 
Figure 3. miR-146a–deficient T cells are hyperactive in chronic inflammatory response in vivo and promote the development of T cell–
associated autoimmunity. (A) Schematic representation of the experimental design to study the role of miR-146a as an autonomous factor to regulate 
T cell response in a chronic T cell inflammatory autoimmune mouse disease model. (B) Flow cytometry analysis to quantify the number of WT and  
miR-146a/ CD4 or CD8 T cells (gated as CD4+ and CD8+, respectively) in the SP of recipient mice on day 29 after adoptive transfer. (C) BrdU incorpora-
tion analysis of the in vivo proliferation of WT and miR-146a/ CD4 and CD8 T cells (gated as CD4+BrdU+ and CD8+BrdU+, respectively) in the SP of re-
cipient mice on day 29 after adoptive transfer. BrdU was injected into recipient mice 16 h before the analysis. (D) Annexin V staining analysis of the in 
vivo apoptosis of WT and miR-146a/ CD4 and CD8 T cells (gated as CD4+Annexin V+ and CD8+Annexin V+, respectively) in the SP of recipient mice on 
day 29 after adoptive transfer. (E and F) Immunohistology analysis of tissue sections from recipient mice on day 29 after adoptive transfer. Tissue sec-
tions from RAG1/ mice that did not receive cell transfer were included as control. (E) Hematoxylin and eosin staining. Arrows point to mononuclear cell 
infiltrates. (F) Anti–mouse CD3 staining. CD3 is shown in brown. Bars: (E, lung, liver, and kidney) 200 µm; (E, stomach) 400 µm; (F) 40 µm. Data are pre-
sented as mean ± SEM (n = 4) and are representative of three independent experiments. *, P < 0.05; **, P < 0.01 (miR-146a/ T cells in comparison with 
the corresponding WT T cells).
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Multiple subunits of NF-B are in-
volved in TCR-induced NF-B acti-
vation (Schulze-Luehrmann and Ghosh, 
2006); we therefore analyzed the composition of NF-B com-
plexes induced by TCR stimulation in WT and miR-146a/ 
T cells. As shown in Fig. 5 E, despite the difference in overall 
NF-B activity, similar NF-B complexes containing p50, 
p65, and c-Rel were induced in both types of T cells, suggest-
ing that miR-146a regulates the activation of TCR-induced 
NF-B without significantly altering the involvement of the 
various NF-B subunits.
miR-146a regulation of TCR-driven NF-B activation 
was also verified by increased nuclear translocation of multiple 
NF-B subunits (p50, p65, and c-Rel) in miR-146a/ T cells 
compared with WT T cells (Fig. 5 F). The steady-state expres-
sion of these NF-B subunits in T cells is not affected by 
miR-146a deficiency (not depicted), indicating that miR-146a 
mainly regulates the activation status of these NF-B subunits. 
Notably, no significant difference of TCR-driven activation of 
NFAT and AP-1 was observed between miR-146a/ and WT 
T cells (not depicted), suggesting that NF-B activation is the 
key TCR-induced signaling event modulated by miR-146a.
To verify the role of miR-146a as a negative regulator of 
NF-B activation, we constructed a retroviral vector, MIG–
miR-146a, that expresses miR-146a (Fig. 5 G). As expected, 
in contrast to miR-146a deficiency, overexpression of miR-
146a in WT T cells through MIG–miR-146a transduction 
significantly down-regulated the NF-B activity induced by 
TCR stimulation (Fig. 5 H). These experimental results estab-
lish a role for miR-146a as a negative feedback regulator mod-
ulating NF-B activation induced by TCR stimulation in 
mouse CD4+ and CD8+ T cells, prompting us to investigate its 
influence on T cell activation that are under NF-B control.
studying the expression of miR-146a in mature CD4+ and 
CD8+ T cells, its interaction with the NF-B pathway upon 
TCR stimulation, and its regulation of T cell activation.
miR-146a modulates TCR-induced activation  
of NF-B in CD4+ and CD8+ T cells
Work from us and others has implicated miR-146a as a 
negative feedback regulator of NF-B activation in innate 
immune cells (Taganov et al., 2006; Williams et al., 2008; 
Hou et al., 2009; Boldin et al., 2011; Zhao et al., 2011). 
This prompted us to investigate the role of miR-146a in 
regulating NF-B activity in T cells, given that NF-B ac-
tivation is a critical signaling event induced by TCR stimu-
lation (Schulze-Luehrmann and Ghosh, 2006). Analysis of 
SP and LN cells containing peripheral T cells that were 
stimulated with anti-CD3/CD28 revealed the induction of 
higher (1.5–2-fold) levels of NF-B activity in miR-146a/ 
cells compared with WT cells as measured in an electro-
phoretic mobility shift assay (EMSA; Fig. 5 A), indicating 
that miR-146a negatively regulates the TCR-induced NF-B 
activation in resting T cells. Analysis of purified CD4+ and 
CD8+ T cells confirmed the up-regulation of NF-B ac-
tivity in both types of T cells in the absence of miR-146a 
(Fig. 5, C and D). In addition to resting T cells, we also 
found an 1.5–2-fold higher induction of NF-B in preac-
tivated miR-146a/ T cells that were restimulated with 
anti-CD3/CD28 compared with their WT counterpart 
(Fig. 5 B), indicating that miR-146a also negatively regu-
lates the NF-B activity induced in activated T cells by 
repetitive TCR stimulation.
Figure 4. miR-146a is expressed in T cells 
and is up-regulated upon TCR stimulation 
through NF-B–dependent induction. (A) Taq-
Man quantitative PCR (Q-PCR) analysis of miR-
146a expression in thymocytes and in total CD4+ 
T cells, CD4+CD25+ Treg cells, CD4+ T cells deprived 
of Treg cells (CD4+CD25), and CD8+ T cells puri-
fied from the SP of 6-wk-old B6 WT mice. Cells 
harvested from the age-matched miR-146a/ 
mice were included as negative control to show 
the specificity of the assay. (B) TaqMan Q-PCR 
analysis of miR-146a expression in WT CD4+ and 
CD8+ T cells or CD4+ and CD8+ T cells lacking NF-B  
component p50 (p50/) or c-Rel (c-Rel/)  
purified from SP cells stimulated with anti-CD3/
CD28 for the indicated time. (C) TaqMan Q-PCR 
analysis of miR-146a expression in thymocytes 
and peripheral CD4+ and CD8+ T cells purified 
from the SP of WT mice or mice deficient of NF-B 
component p50 (p50/) or c-Rel (c-Rel/).  
Data are presented as mean ± SEM (n = 3) and 
are representative of three independent experi-
ments. **, P < 0.01 (miR-146a/ cells in com-
parison with the corresponding WT cells).
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Cyclin-D2, c-Myb, and c-Myc), survival (IL-2, Bcl-2, Bcl-XL, 
and c-FLIP), the effector phenotype (CD25 and CD69), and 
effector cytokine production (IL-2, IFN-, and IL-17A; Li 
and Verma, 2002; Vallabhapurapu and Karin, 2009). In light 
of the finding that miR-146a is a negative feedback regulator 
of TCR-induced NF-B activation in mouse T cells, we asked 
whether miR-146a physiologically regulates these various 
miR-146a regulates the various aspects  
of mouse T cell activation induced by TCR  
stimulation in an NF-B–dependent manner
TCR-induced NF-B activation regulates the expression of 
a large set of NF-B responsive genes involved in almost all 
aspects of T cell activation, among which are those well char-
acterized to be responsible for proliferation (IL-2, Cyclin-D1, 
Figure 5. miR-146a modulates NF-B 
activity in T cells induced by TCR stimula-
tion. (A and B) EMSA of 10 µg of nuclear 
extracts from freshly isolated WT and miR-
146a/ SP and LN cells stimulated with anti-
CD3 + anti-CD28 (1 µg/ml each) for the 
indicated time (A) or from WT and miR-
146a/ SP/LN cells prestimulated with anti-
CD3 + anti-CD28 (1 µg/ml each) for 3 d and 
then rested and restimulated with plate-
bound anti-CD3 (10 µg/ml) and anti-CD28 
(1 µg/ml) for the indicated time (B). Represen-
tative EMSA images and the measurements of  
NF-B in arbitrary units (mean ± SEM; WT 0 h = 1)  
from three independent experiments are 
shown. (C and D) EMSA of 10 µg of nuclear 
extracts from purified WT or miR-146a/ 
CD4 (C) and CD8 (D) T cells stimulated with 
plate-bound anti-CD3 (10 µg/ml) and anti-
CD28 (1 µg/ml) for 2 h. Representative EMSA 
images and the measurements of NF-B in 
arbitrary units (mean ± SEM; WT = 1) from 
three independent experiments are shown.  
(E) Composition of NF-B complexes induced 
by TCR stimulation in WT and miR-146a/ 
CD4 and CD8 T cells assessed by EMSA with 
antibody supershift. 5 µg of specific antibod-
ies to each NF-B component was preincubated 
with 20 µg of nuclear extracts before addition 
of the NF-B probe. Nuclear extracts were 
prepared from purified WT and miR-146a/  
CD4 or CD8 T cells stimulated with plate-
bound anti-CD3 (10 µg/ml) and anti-CD28  
(1 µg/ml) for 20 h. The mobilities of the inducible 
B-binding activities are indicated by arrows. 
The supershifts of B-binding mobilities in-
duced by antibody inhibition are marked with 
“*.” Data are representative of three indepen-
dent experiments. (F) Western blot analysis of 
30 µg of nuclear extracts from WT and miR-
146a/ SP/LN cells stimulated with anti-CD3 
+ anti-CD28 (1 µg/ml each) for the indicated 
time for the expression of p50, p65, and c-Rel. 
Numbers under Western blots denote relative 
amounts normalized to Lamin A expression 
for each sample. Data are representative of three independent experiments. (G) Schematic representation of MSCV retroviral vector expressing GFP re-
porter gene (MIG) and MIG vector expressing murine miR-146a (MIG–miR-146a). IRES, internal ribosome entry site; LTR, long term repeats; MSCV, murine 
stem cell virus; WRE, woodchuck responsive element. (H) EMSA of 20 µg of nuclear extracts from WT SP/LN cells that were prestimulated with anti-CD3 + 
anti-CD28 (1 µg/ml each) for 3 d and transduced with either the control retroviral vector (MIG) or retroviral vector expressing miR-146a (MIG–miR-146a) 
and then were rested and restimulated with plate-bound anti-CD3 (10 µg/ml) and anti-CD28 (1 µg/ml) for 2 h. Representative EMSA image and the mea-
surements of NF-B in arbitrary units (mean ± SEM; WT cells transduced with MIG = 1) from three independent experiments are shown. *, P < 0.05; 
**, P < 0.01 (miR-146a/ samples in comparison with the corresponding WT controls [A–D]; MIG–miR-146a–transduced sample in comparison with the 
corresponding MIG-transduced control [H]).
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Figure 6. miR-146a regulates the various aspects of T cell activation induced by TCR stimulation. (A) [3H]Thymidine incorporation analysis of 
proliferation of purified WT or miR-146a/ CD4 and CD8 T cells stimulated with plate-bound anti-CD3 (10 µg/ml) + anti-CD28 (1 µg/ml) for 4 d. (B) Annexin V 
staining analysis for apoptosis of WT or miR-146a/ CD4 and CD8 T cells (gated as CD4+ and CD8+ from the SP/LN cell culture, respectively) stimulated 
with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 4 d. (C) Flow cytometry analysis of surface activation marker expression on WT or miR-146a/ 
CD4 and CD8 T cells (gated as CD4+ and CD8+ from the SP/LN cell culture, respectively) stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for  
3 d. (D) ELISA analysis of effector cytokine production of purified WT or miR-146a/ CD4 and CD8 T cells stimulated with plate-bound anti-CD3 (10 µg/ml) + 
anti-CD28 (1 µg/ml) for 4 d. (E) Flow cytometry analysis of surface activation marker expression on WT CD4 and CD8 T cells transduced with MIG–miR-146a 
or control MIG retroviral vectors and stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d (gated as CD4+GFP+ and CD8+GFP+ from the 
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analysis revealed that miR-146a deficiency only altered the 
late expression of these NF-B target genes without affecting 
their early expression (Fig. 6 J), strongly supporting the role 
of miR-146a as a negative feedback regulator of NF-B acti-
vation in T cells. However, induction of certain other genes 
that have also been found to be NF-B responsive was not 
affected in the absence or excess of miR-146a, including 
Cyclin-D1, Cyclin-D2, c-Myb, c-Myc, and c-FLIP (not depicted). 
This might be caused by an NF-B sensitivity of these genes 
that is beyond the regulatory range of miR-146a or by the 
ability of other transcription factors to mask the effect.
Finally, we analyzed the influence of miR-146a on T cell 
activation in the absence of p50, the key component of most 
NF-B complexes induced by TCR stimulation in mouse 
T cells. No difference between p50/ and p50/miR-146a/ 
T cells upon TCR stimulation was evident studying sur-
face activation marker expression (Fig. 7, A and B), prolif-
eration (Fig. 7 C), survival (Fig. 7 D), and effector cytokine 
production (Fig. 7 E). This suggests that the regulatory 
function of miR-146a on T cell activation is mainly mediated 
through regulation of NF-B, especially its p50 subunit. 
Notably, the production of IL-17A still showed certain 
difference between p50/ and p50/miR-146a/ T cells 
(Fig. 7 E), suggesting the involvement of p50-negative NF-B 
complexes or other signaling pathways that are also under 
regulation of miR-146a for the induction of this cytokine.
IL-2 is a major cytokine induced by NF-B activation 
downstream of TCR stimulation and has been found to par-
ticipate in many aspects of T cell activation (Malek, 2008). 
Because miR-146a was shown to regulate IL-2 production 
(Fig. 6, D and H), it brings up the possibility that miR-146a 
might regulate T cell activation mainly through its effect on 
IL-2. However, neutralizing of IL-2 in T cell culture only par-
tially abrogated the difference between WT and miR-146a/  
T cells in response to TCR stimulation (Fig. 8, A–C), indicat-
ing that miR-146a regulation of T cell activation is not totally 
mediated through regulating IL-2 production, but rather 
likely through modulating the expression of multiple NF-B 
responsive genes.
Overall, these data suggest that miR-146a regulates the 
various aspects of T cell activation upon TCR stimulation in 
an NF-B–dependent manner, likely through modulating the 
aspects of mouse T cell activation and whether such regula-
tion is mediated through NF-B. To address these ques-
tions, first we conducted an extensive comparison of WT 
and miR-146a/ T cells in response to anti-CD3/CD28 
stimulation, focusing on those activities that are under 
NF-B regulation. We found that compared with their 
WT counterparts, miR-146a/ CD4+ and CD8+ T cells 
were overall hyperactive, manifested by higher proliferation 
(Fig. 6 A), diminished apoptosis (Fig. 6 B), an exaggerated 
effector phenotype with particularly high surface activation 
markers CD25 (IL-2R) and CD69 (Fig. 6 C), and in-
creased production of effector cytokines including IL-2, 
IFN-, and IL-17A (Fig. 6 D). Of note, before anti-CD3/
CD28 stimulation, both WT and miR-146a/ T cells exhib-
ited a similar naive T cell phenotype (CD25CD69CD62
LhiCD44lo; not depicted), suggesting that the observed differ-
ences between WT and miR-146a/ T cells ensued after 
TCR stimulation. On the contrary, overexpression of miR-
146a in WT T cells through MIG–miR-146a–mediated 
transduction resulted in hypoactivation in response to 
anti-CD3/CD28 stimulation, shown as reduced prolifera-
tion (Fig. 6 F), enhanced apoptosis (Fig. 6 G), a dampened 
effector phenotype that was particularly lower in surface ac-
tivation markers CD25 and CD69 (Fig. 6 E), and reduced 
production of effector cytokines (Fig. 6 H). Thus, these re-
sults indicate that miR-146a plays a physiological role of 
negatively modulating the various aspects of mouse T cell 
activation that are under NF-B regulation.
Next we analyzed the induction of the NF-B responsive 
genes that are involved in T cell activation under the influ-
ence of miR-146a. After stimulation with anti-CD3/CD28, 
cells lacking miR-146a exhibited a significantly augmented 
induction of a set of NF-B responsive genes, including 
Bcl-2, Bcl-XL, CD25, CD69, IL-2, IFN-, and IL-17A; 
conversely, overexpression of miR-146a in mouse T cells 
through MIG–miR-146a transduction resulted in a signifi-
cantly decreased induction of these genes (Fig. 6 I). Analysis 
of the induction of these genes in purified CD4+ and CD8+ 
T cells confirmed that these genes were subjected to miR-146a 
regulation in both types of T cells (not depicted). Thus, miR-
146a modulates the induction of genes that are under NF-B 
regulation after TCR stimulation. Moreover, time course 
SP/LN cell culture, respectively). (F) Relative cell number fold change of WT CD4 and CD8 T cells transduced with MIG–miR-146a or control MIG retroviral 
vectors and stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d (gated as CD4+ and CD8+ from the SP/LN cell culture, respectively; 
counts of T cells transduced with MIG = 1). (G) Annexin V staining of WT CD4 and CD8 T cells transduced with MIG–miR-146a or control MIG retroviral 
vectors and stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 4 d (gated as CD4+GFP+ and CD8+GFP+ from the SP/LN cell culture, respec-
tively). (H) ELISA analysis of effector cytokine production of WT SP/LN cells transduced with MIG–miR-146a or control MIG retroviral vectors and stimu-
lated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 4 d. (I) TaqMan Q-PCR analysis of the expression of NF-B responsive genes in WT and 
miR-146a/ SP/LN cells stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d (top) or in WT SP/LN cells transduced with either MIG-
miR-146a or control MIG retroviral vector and stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d (bottom). RE, relative expression.  
(J) TaqMan Q-PCR analysis of the time course expression of NF-B responsive genes in WT and miR-146a/ SP/LN cells stimulated with soluble anti-CD3 + 
anti-CD28 (1 µg/ml each) for 5 d. Data are presented as mean of duplicate culture ± SEM (A, B, D, and F–I) and are representative of three independent 
experiments. *, P < 0.05; **, P < 0.01 (miR-146a/ samples in comparison with the corresponding WT controls [A, B, D, and I, top]; MIG–miR-146a– 
transduced samples in comparison with the corresponding MIG-transduced controls [F–H and I, bottom]).
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and IRAK1, two adaptor molecules involved in the NF-B 
activation pathway (Oeckinghaus et al., 2011) which are targets 
of miR-146a inhibition in epithelial cells, innate immune 
cells, and B cells (Taganov et al., 2006; Nahid et al., 2009; 
Chassin et al., 2010; Boldin et al., 2011). Mouse SP/LN cells 
stimulated with anti-CD3/CD28 for 3 d displayed an 1.8-
fold increase 
of TRAF6 
and an 2.5-
fold increase 
of IRAK1 at 
the protein 
expression of a set of NF-B responsive genes involved in 
these activities. This finding encouraged us to further investigate 
the molecular mechanisms underlying the miR-146a modu-
lation of TCR signaling to NF-B.
TRAF6 and IRAK1 are bona fide targets of miR-146a  
in mouse CD4+ and CD8+ T cells and are possible mediators 
for its regulation of TCR-induced NF-B activity
miRNAs function through posttranscriptional repression of 
their target genes (Ambros, 2004; Bartel, 2004). Among the 
many possible targets of miR-146a predicted by computa-
tional algorisms, we were particularly interested in TRAF6 
Figure 7. miR-146a regulates T cell activation in an NF-B–dependent manner. (A and B) Flow cytometry analysis of surface activation marker 
expression on resting (A; gated as CD4+ and CD8+ from the SP cells freshly isolated from 6-wk-old mice) or activated (B; gated as CD4+ and CD8+ from 
the SP/LN cells stimulated with 1 µg/ml soluble anti-CD3 + 1 µg/ml soluble anti-CD28 for 3 d) p50/ and p50/miR-146a/ CD4 and CD8 T cells.  
(C) [3H]Thymidine incorporation analysis of proliferation of SP/LN cells harvested from p50/ or p50/miR-146a/ mice and stimulated with soluble 
anti-CD3 + anti-CD28 (1 µg/ml each) for 4 d. (D) Annexin V staining of p50/ and p50/miR-146a/ CD4 and CD8 T cells stimulated with soluble anti-
CD3 + anti-CD28 (1 µg/ml each) for 4 d (gated as CD4+ and CD8+ from the SP/LN cell culture, respectively). (E) ELISA analysis of effector cytokine production of 
p50/ and p50/miR-146a/ SP/LN cells stimulated with soluble anti-CD3 and anti-CD28 (1 µg/ml each) for 4 d. Data are normalized to the input T cells  
in SP/LN cell culture. Data are presented as mean of duplicate culture ± SEM and are representative of three independent experiments. **, P < 0.01 (p50/ 
miR-146a/ samples in comparison with the corresponding p50/ controls; for time course experiment, statistics of the peak responses  
are shown).
Figure 8. miR-146a regulation of T cell activa-
tion is not totally mediated through regulating  
IL-2 production. (A–C) WT and miR-146a/ SP/LN cells 
containing equal number of T cells were stimulated 
with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 
3 d in the presence or absence of 10 µg/ml anti–IL-2 
neutralizing antibody or isotype control antibody.  
(A) [3H]Thymidine incorporation analysis of the prolif-
eration of WT and miR-146a/ cells on day 3 after 
anti-CD3/CD28 stimulation. (B) Annexin V staining of 
WT and miR-146a/ CD4 and CD8 cells (gated as 
CD4+ and CD8+ from the SP/LN cell culture, respec-
tively) on day 3 after anti-CD3/CD28 stimulation.  
(C) ELISA analysis of effector cytokine production of 
WT and miR-146a/ cells on day 2 (for IL-2) or day 3 
(for IFN- and IL-17A) after anti-CD3/CD28 stimula-
tion. The time points are chosen to represent the peak 
production of the corresponding cytokines during the 
3-d time course experiment. Data are presented as 
mean of duplicate culture ± SEM and are representa-
tive of three independent experiments. *, P < 0.05; 
**, P < 0.01 (miR-146a/ cells in comparison with the 
corresponding WT control cells).
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NF-B activation is a key signaling event downstream of TCR 
engagement and regulates almost all of the important aspects 
of T cell activation. Because of its pivotal role, NF-B acti-
vation in T cells is regulated through a multilayered negative 
regulatory network (Schulze-Luehrmann and Ghosh, 2006). 
In this study, we identified miR-146a as an important new 
member of the negative feedback loop that modulates TCR 
signaling to NF-B and demonstrated its physiological role in 
regulating both acute T cell response and chronic hyperin-
flammatory autoimmune T cell response in vivo. Based on 
these results, we propose a model of miR-146a as an impor-
tant new constituent of the negative feedback regulatory net-
work modulating TCR signaling to NF-B. In this model, 
TCR stimulation activates NF-B which induces the expres-
sion of miR-146a. miR-146a in turn down-regulates NF-B 
activation through repressing NF-B activators TRAF6 and 
IRAK1, providing a negative feedback control for the induc-
tion of NF-B responsive genes that are involved in the vari-
ous aspects of T cell activation. Therefore, our study adds 
miRNA, a key emerging posttranscriptional regulator of the 
immune system, as a novel molecular player controlling reso-
lution, a critical physiological aspect of T cell responses.
Including miR-146a, three molecules have been identi-
fied that act in negative feedback loops modulating TCR 
signaling to NF-B (the other two are IB and A20). It is 
interesting to ask why nature evolved so many pathways for 
this regulation. The answer is not redundancy because mice 
defective in any one of these three molecules develop auto-
immune symptoms (Beg et al., 1995; Klement et al., 1996; 
Lee et al., 2000; Boldin et al., 2011). However, these three 
molecules enact their regulatory functions with distinct ki-
netics. IB and A20 belong to the Group I NF-B early 
responsive genes whose expression is rapidly induced after 
NF-B activation and peaks within 0.5 h and then are quickly 
down-regulated (Hoffmann et al., 2002; Werner et al., 2008; 
Hao and Baltimore, 2009). Newly made IB is particularly 
important for two perspectives: (1) it binds to nuclear NF-B, 
shuttling it to the cytoplasm and terminating the response to 
a pulse of induction shorter than 30 min; and (2) if induction 
persists longer, it generates oscillations of active, nuclear NF-B 
(Hoffmann et al., 2002). A20 provides a rheostat function, 
quickly reducing the secondary phases of NF-B activity and 
possibly serving as a signaling cross talk mediator (Hoffmann 
et al., 2002; Werner et al., 2008). In contrast, miR-146a expres-
sion in TCR-stimulated T cells gradually increases through 
the time course of T cell activation (Fig. 4 B). These results 
put miR-146a into the group III NF-B late responsive 
genes (Hao and Baltimore, 2009) and imply that it may have 
a gradually increased impact on NF-B activity over the later 
course of induction. This notion is supported by our results 
of time course comparison of NF-B activation in WT and 
miR-146a/ T cells after TCR stimulation (not depicted). 
Similar to A20, miR-146a targets signaling molecules in the 
NF-B pathway (e.g., TRAF6 and IRAK1) that are shared 
with other signaling pathways and therefore may have a simi-
lar rheostat function in addition to regulating NF-B activation 
expression level in miR-146a/ cells compared with WT 
cells (Fig. 9, A and B). On the contrary, overexpression of 
miR-146a in WT SP/LN cells stimulated with anti-CD3/
aCD28 reduced the protein expression of TRAF6 for 1.4-
fold and for IRAK1 up to 10-fold (Fig. 9, C and D). Analysis 
of purified CD4+ and CD8+ T cells confirmed an up-regula-
tion of TRAF6 and IRAK1 proteins in both types of T cells 
in the absence of miR-146a (Fig. 9 E). Collectively, these 
results demonstrate TRAF6 and IRAK1 to be bona fide 
targets of miR-146a in primary mouse CD4+ and CD8+  
T cells. To verify the connection between the up-regulated 
expression of TRAF6 and IRAK1 and the elevated activation 
of NF-B in activated T cells lacking miR-146a, we con-
structed retroviral vectors expressing TRAF6 (MIG-TRAF6) 
and IRAK1 (MIG-IRAK1). Transduction of activated WT 
T cells with MIG-TRAF6 or MIG-IRAK1 resulted in an 
overexpression of IRAK1 or TRAF6 (Fig. 9 F) to a level sim-
ilar to that observed in activated miR-146a/ T cells (Fig. 9 B). 
Importantly, this up-regulation of TRAF6 and IRAK1 ex-
pression correlated with an increased induction of NF-B ac-
tivity after TCR stimulation (Fig. 9 G), which was similar to 
that observed in miR-146a/ cells (Fig. 5 B), suggesting that 
TRAF6 and IRAK1 are possible mediators of the miR-146a 
regulation of NF-B activation in primary mouse T cells. 
Consistent with their increased NF-B activity, WT T cells 
overexpressing TRAF6 or IRAK1 showed enhanced prolif-
eration, survival, and effector cytokine production in response 
to TCR stimulation (Fig. 9, H–J). In a complementary experi-
ment, reduction of TRAF6 or IRAK1 expression in miR-
146a/ T cells through small interfering RNA (siRNA) 
targeting partially corrected their hyperactivation phenotype 
after TCR stimulation, further supporting the roles of these 
two signaling proteins in mediating miR-146a regulation of 
T cell activation (Fig. 9, K–N). Interestingly, changes of T cell 
activation induced by manipulating the expression of TRAF6 
or IRAK1 are not identical: TRAF6 seems to impact more on 
proliferation (Fig. 9, H and L) and the production of IL-2 
(Fig. 9, J and N), whereas IRAK1 seems to impact more on 
survival (Fig. 9, I and M) and the production of IL-17A (Fig. 9, 
J and N). These results suggest that miR-146a regulation of 
T cell activation is likely mediated through its combinatorial 
modulation of multiple targets including TRAF6 and IRAK1. 
Notably, in contrast to TRAF6 and IRAK1, analysis of other 
signaling components mediating TCR signaling to NF-B 
including the CBM complex showed no obvious difference 
in their steady-state expression levels between miR-146a/ 
and WT T cells (not depicted), suggesting that TRAF6 and 
IRAK1 are likely to be the major targets of miR-146a modu-
lating TCR signaling to NF-B.
DISCUSSION
As the central player in the immune response fighting against 
pathogen invasions in mammals, the activation of T cells must 
be tightly regulated. Proper resolution of a T cell response 
is as essential as its initiation because of the possible severe 
pathological consequences of a hyperinflammatory response. 
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Figure 9. TRAF6 and IRAK1 are bona fide targets of miR-146a in mouse T cells and are possible mediators for its regulation of NF-B  
activity. (A and B) TaqMan Q-PCR analysis of miR-146a expression (A; shown as mean of duplicates ± SEM) and Western blot analysis of TRAF6 and 
IRAK1 expression (B) in WT or miR-146a/ SP/LN cells stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d. Data are representative of 
three independent experiments. (C and D) TaqMan Q-PCR analysis of miR-146a expression (C; shown as mean of duplicates ± SEM) and Western blot 
analysis of TRAF6 and IRAK1 expression (D) in WT SP/LN cells transduced with MIG–miR-146a or control MIG retroviral vectors and stimulated with solu-
ble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d. Data are representative of three independent experiments. (E) Western blot analysis of TRAF6 and IRAK1 
expression in activated WT or miR-146a/ CD4 and CD8 T cells. CD4 and CD8 T cells were purified through MACS sorting from WT or miR-146a/ SP/LN cells 
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IRAK1 participate in other signaling pathways that are involved 
in T cell responses (King et al., 2006; Maitra et al., 2009; 
Pearce et al., 2009). For instance, TRAF6 regulates CD4+ T cell 
suppression by Treg cells through the PI3K (phosphatidylino-
sitol 3-kinase)–Akt pathway (King et al., 2006), and it regu-
lates CD8+ T cell memory development through the fatty 
acid metabolism pathway (Pearce et al., 2009). IRAK1 has 
been implicated in regulation of the differentiation of Th17 
and Treg cells through modulating the relative activity of 
STAT3 and NFAT signaling pathways (Maitra et al., 2009). 
Therefore, targeting TRAF6 and IRAK1 allows miR-146a 
to modulate the cross talk between NF-B and multiple 
other signaling pathways, supporting its rheostat role as pro-
posed by our NF-B negative feedback temporal control 
model. Moreover, besides TRAF6 and IRAK1, several other 
putative targets of miR-146a have been evaluated in T cells 
and have been implicated in miR-146a regulation of T cell 
function, including Stat1, which is involved in the IFN- 
receptor signaling pathway, and FADD (Fas-associated death 
domain), which is involved in the T cell apoptosis pathway 
(Curtale et al., 2010; Lu et al., 2010). Although our observa-
tion of a largely abrogated miR-146a regulatory function in 
T cells defective in the NF-B subunit p50 strongly suggests 
that modulation of NF-B activity through targeting TRAF6/
IRAK1 is a predominant mechanism that miR-146a utilizes to 
regulate T cell activation, it does not exclude the participation 
of other miR-146a targets and their related signaling path-
ways. In fact, the multi-targeting nature of miRNAs enables 
them to simultaneously regulate multiple signaling events. 
The identification of further miR-146a targets in T cells, the 
dissection of miR-146a regulatory function into its modulation 
of individual target molecules, and the characterization of its 
overall modulation of specialized signaling network that lead to 
its control of T cell responses under various physiological and 
pathological conditions will be interesting topics for future study.
Our study indicates miR-146a to be a T cell–autonomous 
factor that not only regulates the resolution of acute T cell 
and may also serve as a mediator to modulate the cross talk 
between NF-B pathways and other signaling pathways. For 
T cells, these three negative feedback regulators may form a 
temporal control to ensure proper resolution of T cell re-
sponse after antigen stimulation: IB providing a potent but 
transient negative control at the initial phase of T cell activa-
tion, followed by A20 acting mainly at the early phase of 
T cell activation, and miR-146a providing a long-lasting 
negative control at the late phase. This working hypothesis is 
supported by our observation that miR-146a deficiency has a 
more profound impact on the late-phase (contraction phase 
and stabilization phase) antigen-specific T cell response in 
vivo (Fig. 1 B). Unfortunately, the in vivo T cell response 
data are lacking for mice defective in IB or A20, likely be-
cause of their early lethality (Beg et al., 1995; Klement et al., 
1996; Lee et al., 2000). New mouse models that are condi-
tionally knocked out of these two genes in the T cell com-
partment, alone or in combination with miR-146a deficiency, 
will provide valuable insights into the precise role of each of 
the NF-B negative feedback regulators and their joint tem-
poral control of the resolution of T cell response.
Our study demonstrated TRAF6 and IRAK1 to be bona 
fide targets of miR-146a in T cells that presumably mediate 
part or all of the regulation of TCR-induced NF-B activity, 
extending our previous findings that these two signaling 
adaptor molecules are targets of miR-146a in monocytes and 
B cells (Taganov et al., 2006; Boldin et al., 2011). In TCR 
signaling to NF-B, TRAF6 has been shown to mediate 
the signal transmission from the CBM signalosome to IKK 
through Lys-63–linked polyubiquitination of IKK (NEMO; 
Sun et al., 2004). Interaction of IRAK1 with the TCR to 
NF-B signaling cascade remains to be demonstrated, but by 
analogy to its position in NF-B signaling cascades down-
stream of TLR (Toll-like receptor) and the IL-1R families in 
innate immune cells, it may also be positioned between the 
CBM signalosome and IKK (Oeckinghaus et al., 2011). It is 
noteworthy that aside from the NF-B pathway, TRAF6 and 
stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) for 3 d. Data are representative of three independent experiments. (F–J) WT SP/LN cells  
were stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) and transduced with MIG-TRAF6, MIG-IRAK1, or control MIG retroviral vectors.  
By day 3, >90% of total cell culture was activated T cells (sum of CD4+ and CD8+ cells). Data are representative of at least three independent experiments. 
*, P < 0.05; **, P < 0.01 (MIG-TRAF6– or MIG-IRAK1–transduced samples in comparison with the corresponding MIG-transduced controls). (F) Western 
blot analysis of TRAF6 and IRAK1 expression in day 3 transduced cells. (G) EMSA analysis of NF-B activity of 10 µg of nuclear extracts from day 3 trans-
duced cells rested and restimulated with plate-bound anti-CD3 (10 µg/ml) + anti-CD28 (1 µg/ml) for 30 min. Representative EMSA image and the mea-
surements of NF-B in arbitrary units (mean ± SEM; cells transduced with MIG = 1) from three independent experiments are shown. (H) Relative CD4 and 
CD8 T cell number (gated as CD4+ and CD8+, respectively, cell count of MIG-transduced T cells = 1) on day 3. Data are presented as mean of duplicate 
culture ± SEM. (I) Annexin V staining analysis of apoptosis of transduced CD4 and CD8 T cells (gated as CD4+GFP+ and CD8+GFP+, respectively) on day 4. 
Data are presented as mean of duplicate culture ± SEM. (J) ELISA analysis of effector cytokine production from transduced cells on day 3. Data are pre-
sented as mean of duplicate culture ± SEM. (K–N) WT or miR-146a/ SP/LN cells were stimulated with soluble anti-CD3 + anti-CD28 (1 µg/ml each) and 
transfected with nonsilencing control siRNA (siCtrl) or siRNA specific for mouse TRAF6 (siTRAF6) or IRAK1 (siIRAK1). Representative data from two inde-
pendent experiments are shown. *, P < 0.05; **, P < 0.01 (miR-146a/ cells transduced with various siRNAs in comparison with WT cells transduced with 
control siRNA). (K) Western blot analysis of TRAF6 and IRAK1 expression in the siRNA-transfected cells on day 3.5. (L) [3H]Thymidine incorporation analy-
sis of proliferation of the siRNA-transfected cells on day 3. Data are presented as mean of duplicate culture ± SEM. (M) Annexin V staining analysis of 
apoptosis of the siRNA-transfected CD4 and CD8 T cells (gated as CD4+ and CD8+, respectively) on day 3.5. Data are presented as mean of duplicate cul-
ture ± SEM. (N) ELISA analysis of effector cytokine production from the siRNA-transfected cells on day 3.5. Data are presented as mean of duplicate cul-
ture ± SEM. Numbers under Western blots denote relative amounts normalized to -actin or PLC-1 expression for each sample.
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California Institute of Technology, Pasadena, CA) were bred at the California 
Institute of Technology. miR-146a/ mice in C57BL/6J background were 
generated and maintained at the California Institute of Technology (Boldin 
et al., 2011). p50/miR-146a/ mice were generated through breeding 
p50/ and miR-146a/ mice (Zhao et al., 2011). OT1 Tg mice deficient 
of miR-146a were generated through breeding OT1 Tg mice with miR-
146a/ mice. All mice were housed in the California Institute of Technol-
ogy animal facility in accordance with institute regulations. 6–8-wk-old 
female mice were used for all experiments unless otherwise indicated. Animal 
experiments were approved by the Institutional Animal Care and Use Com-
mittees of the California Institute of Technology.
OVA257–269 peptide was purchased from GenScript. Polybrene was pur-
chased from Millipore. MACS sorting reagents were purchased from Milte-
nyi Biotec.
Antibodies and flow cytometry. Stimulatory anti–mouse CD3 (clone 
145-2C11) and anti–mouse CD28 (clone 37.51) antibodies and neutralizing 
anti–mouse IL-2 (clone JES6-1A12) and isotype control (rat IgG2a, ) anti-
bodies were purchased from BioLegend. Fluorochrome-conjugated antibod-
ies specific for mouse CD4, CD8, CD25 (IL-2R), CD69, CD62L, and CD44 
were purchased from BioLegend and for mouse TCR V5 and Annexin V 
were purchased from BD. Fc Block (anti–mouse CD16/32) was purchased 
from BioLegend. Cells were stained as previously described (Yang and 
Baltimore, 2005) and analyzed using either a FACSCalibur flow cytometer 
(BD) or a MACSQuant (Miltenyi Biotec). FlowJo software (Tree Star) was 
used to analyze the data.
miRNA quantitative RT-PCR. Total RNA was isolated using TRIZOL 
reagent (Invitrogen). miR-146a expression was measured using TaqMan 
miRNA Assays (Applied Biosystems) according to the manufacturer’s 
instructions using a 7300 Real-time PCR thermocycler (Azco Biotech). 
snoRNA202 was used as internal control. The relative expression of miR-
146a was calculated by the 2CT method and was presented as the fold in-
duction relative to 210 snoRNA202.
Messenger RNA (mRNA) quantitative RT-PCR. Total RNA was iso-
lated using TRIZOL reagent (Invitrogen). cDNA was prepared using a 
SuperScript III First-Strand Synthesis kit (Invitrogen). Gene expression was 
measured using TaqMan Gene Expression Assays (Applied Biosystems) accord-
ing to the manufacturer’s instructions using a 7300 Real-time PCR thermo-
cycler. Ube2d2 was used as an internal control because of its relative constant 
mRNA level during T cell activation (Hamalainen et al., 2001). The relative 
expression of the mRNA of the gene of interest was calculated by the 2CT 
method and was presented as the fold induction relative to 20 Ube2d2.
EMSA. EMSA was performed as previously described (Hoffmann et al., 
2002). Nuclear protein extracts were prepared using Nuclear Protein Ex-
traction kit (Sigma-Aldrich). Nuclear extracts containing equal amounts of 
protein were tested for binding to an NF-B probe containing a consensus 
B-binding site (5-AGCTTGCTACAAGGGACTTTCCGCTGTCTA-
CTTT-3;  NF-B–binding sequence in bold). In antibody supershift assays 
to identify components of NF-B complexes, 5 µg of purified antibodies 
specific to each NF-B components (anti-p50 [Active Motif] and anti-
p65(C-20) and anti–c-Rel(C) [Santa Cruz Biotechnology, Inc.]) was pre-
incubated with nuclear extracts for 15 min on ice before addition of the 
NF-B probe.
Western blot. Western blot was performed as previously described (Boldin 
et al., 2011). Total protein was extracted using RIPA buffer (Thermo Fisher 
Scientific) supplemented with Protease Inhibitor Cocktail (Roche). Nuclear 
protein was extracted using the Nuclear Protein Extraction kit (Sigma-Aldrich). 
Protein extracts were resolved on 10% Bis-Tris NuPAGE gel. The following 
antibodies were used to blot for the protein of interest: anti–mouse IRAK1 
(Cell Signaling Technology), anti–mouse TRAF6 (MBL), anti–NF-B p50 
(Abcam), and anti–NF-B p65 and c-Rel (Santa Cruz Biotechnology, Inc.). 
response but also regulates the resolution of chronic T cell 
hyperinflammatory response and controls the development 
of T cell–associated autoimmunity. Previously, we have 
shown that in miR-146a/ mice, deficiency of miR-146a in 
other cell types may contribute to a hyperinflammatory auto-
immune phenotype (Lu et al., 2010; Boldin et al., 2011; 
Zhao et al., 2011). First, the myeloid overproliferation and 
malignancies in miR-146a/ mice generates an overall 
proinflammatory environment (Zhao et al., 2011); second, 
miR-146a/ macrophages tend to produce an excess amount 
of proinflammatory cytokines (e.g., TNF and IL-6) upon 
stimulation (Boldin et al., 2011); third, miR-146a/ Treg 
cells exhibit impaired capacity to suppress Th1 response 
(Lu et al., 2010). All three defects are well-established contrib-
utors to the development of autoimmune disease. Collectively, 
miR-146a provides a potent negative control for the chronic 
T cell hyperinflammatory response and the development of 
autoimmunity through multiple T cell–intrinsic and –extrin-
sic mechanisms. Notably, miR-146a dysregulation has been 
observed in several human autoimmune diseases, including 
rheumatoid arthritis and systemic lupus erythematosus (Nakasa 
et al., 2008; Stanczyk et al., 2008; Tang et al., 2009), implicating 
miR-146a in the development of these human diseases and sug-
gesting it as a potential therapeutic target treating these diseases.
Consistent with our findings in mouse T cells, TCR stim-
ulation has been implicated in the induction of miR-146a 
expression in human T cells, and the forced expression of 
miR-146a in the human Jurkat T cell line has been shown to 
affect IL-2 production and activation-induced cell death 
(Curtale et al., 2010), supporting the role of miR-146a as a 
feedback regulator in human T cell activation. The interaction 
of miR-146a with the NF-B signaling pathway in human 
T cells and its physiological role in regulating T cell responses 
in humans during infection and during development of auto-
immune diseases are interesting research directions to pursue.
miRNAs as a new class of posttranscriptional regulators 
are emerging as important players in the immune system. In 
T cells, a growing list of miRNAs have been implicated in 
regulating various stages of T cell activation, including miR-
181a regulation of TCR sensitivity to antigen (Li et al., 2007) 
and miR-155 regulation of inflammatory T cell development 
(Rodriguez et al., 2007; Thai et al., 2007; O’Connell et al., 
2010). Our study provides the first in vivo evidence of miR-
146a being a critical physiological controller of the resolution 
of T cell responses, mediated through its targeting of a key 
signaling pathway downstream of TCR stimulation. These 
findings extend the regulatory function of miRNAs to cover 
this important stage of T cell activation and suggest miRNAs 
as attractive therapeutic targets for T cell–based vaccine de-
velopment and for the treatment of autoimmune disorders 
and malignancies.
MATERIALS AND METHODS
Mice and materials. C57BL/6J (B6), B6.SJL-PtprcaPepcb/BoyJ (CD45.1), 
and B6;129S7-Rag1tm1mom/J (RAG1/) mice were purchased from the 
Jackson Laboratory. OT1 Tg mice and p50/ mice (provided by S. Hao, 
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using an Annexin V Apoptosis Detection kit (BD) according to the manu-
facturer’s instructions. For cells cultured in a 96-well plate, at the indicated 
times, cell culture supernatants were collected and assayed for effector cyto-
kine (IL-2, IFN-, and IL-17A) production by ELISA, and the cells were 
pulsed with [3H]thymidine to assay for proliferation.
For purified T cell stimulation, resting CD4 and CD8 T cells were purified 
from SP and LN cells through MACS sorting (positive selection for CD4+ and 
CD8+ cells, respectively) and were cultured at 105 cells/well in a 96-well round-
bottom plate precoated with 10 µg/ml anti-CD3 + 1 µg/ml anti-CD28. At the 
indicated time points, cell culture supernatants were collected and assayed for 
effector cytokine (IL-2, IFN-, and IL-17A) production by ELISA, and the cells 
were pulsed with [3H]thymidine to assay for proliferation.
Statistic analysis. Student’s two-tailed t test was used for paired compari-
sons. Data are presented as mean ± SEM, unless otherwise indicated. P < 0.05 
was considered significant.
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